Preclinical Support & Regulatory Science
Preclinical Support benefits early-stage companies that need help in managing the complexities and uncertainties in translating preclinical/nonclinical (toxicology) data to justify the starting point for first-in-human studies. This is also sometimes referred to as the so-called “valley of death” in emerging-stage companies. That is mainly because of the need to generate clinical data to attract investors without having adequate capital necessary to conduct clinical trials.
Regulatory Science involves translating the FDAs innovation initiatives into practical terms so that you can understand them better. The FDA’s published strategic plan “Advancing Regulatory Science at FDA” identifies eight priority areas of regulatory science where new or enhanced engagement is essential to the continued success of the FDA’s public health and regulatory mission.
Preclinical/Nonclinical support for early-stage companies:
- Help early-stage companies manage the complexities of “translation science” when moving from concept to clinic.
- Explore the FDA’s Predictive Toxicology Roadmap on “Replacement, Reduction and Refinement”
- Define what IND-enabling proof-of-concept studies might mean for your drug candidate as you look ahead to your First-in-Human studies
- Help in justifying a starting point in humans based on nonclinical results
- If needed, help you source and qualify a third-party CMO/CDMO to support your product development and manufacture your clinical trial material.
- Facilitate technology transfer to a CMO/CDMO
- Understand which of the FDA Regulatory Science Priority Areas may contain initiatives that could be beneficial to your current or future development plans. A few key examples include:
- The FDA’s Predictive Toxicology Roadmap
- Innovation in Clinical Evaluations and Personalized Medicine to Improve Product Development and Patient Outcomes
- New Approaches to Improve Product Manufacturing and Quality
- The FDA’s Readiness to Evaluate Innovative Emerging Technologies
- Determine if your drug qualifies for fast-track designation, breakthrough therapy designation, accelerated approval and/or priority review designation
- Identify applicable regulations that apply to your specific drug/medical device and translate them into actionable regulatory strategies early on so that you can forecast and budget your needed cash spend
Resources for Sponsors and Investigators Involved in Rare Disease Drug Development and Families Living with Someone with a Rare Disease
US FDA Video Presentation: “About FDA’s Regulatory Science Program” — CDER Director Dr. Janet Woodcock explains how regulatory science helps FDA to develop new tools, standards, and approaches that assess the safety, efficacy, quality, and performance of drug products. Regulatory science aids the drug development community by supporting and streamlining development and testing of new products. WATCH THE VIDEO
US FDA Video Presentation: “How Regulatory Science Benefits Patients” — CDER Director Dr. Janet Woodcock explains how regulatory science benefits patients by explaining microperfusion. Microperfusion is a new technology that measures the concentration of drugs in the skin. It provides an efficient way to evaluate bioequivalence for prospective generics applied to the skin. WATCH THE VIDEO
Provided CMC strategy, pre-clinical/clinical development and regulatory strategy “road map” for a South Korean company developing a novel microneedle combination product in the US for USFDA approval. In scope will be a pre-IND meeting request.
Provided support to an early-stage oncology cell and gene therapy company by translating FDA nonclinical guidances into a roadmap which will help them identify their lead candidate. Assisting client to conceptualize proof-of-concept study details and plan for other toxicology studies required to support a pre-IND meeting request.
Provided CMC strategy, DMF support, pre-clinical/clinical development and regulatory strategy for cannabinoid company conducting research in opioid-sparing pain. Submitted a pre-IND request, which was accepted. Now working on meeting package.
Provided non-clinical and regulatory support to a not-for-profit research entity pioneering novel treatments for acute myeloid leukemia “AML.” Performed a gap analysis on nonclinical studies conducted and their outcomes against FDA regulations. Provided client with a written report of findings/ recommendations.
Let Ayd Group be Your Sounding Board and Expert Advisor throughout Your Product Development.
We’ll help you understand what’s necessary to develop your drug or medical device.